Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Jean-Francois Millau
CEO
millau.jf@tatumbio.com

Message the company or request a 1:1 meeting here

TATUM bioscience is a synthetic biology company developing a new class of immuno-oncology drugs based on programmed therapeutic bacteria. Using its proprietary synLBT platform, TATUM is advancing candidates to bring disruptive therapies to cancer patient who no longer respond to immune checkpoint inhibitor treatments and are left with no therapeutic solutions.

Executive Summary